Equity Profile
Pre-Earnings Brief
Kiniksa Pharmaceuticals is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Kiniksa aims to address unmet medical needs, making it a significant player in the biotechnology industry.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Total revenue reflects the company's sales performance and growth potential.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
38%
Avg EPS Surprise
-127.87%
Avg Stock Reaction
+4.11%
In the last quarter, Kiniksa reported an EPS of $0.17, which was below analysts' expectations of $0.29, resulting in a negative surprise. The stock reacted by declining 8.21% the following day.
Management Promises & Guidance
Analysts are cautiously optimistic about Kiniksa's upcoming earnings, expecting an EPS of $0.16 and revenue of $206 million. The market is keen to see if the company can meet or exceed these expectations after a series of misses.
Bull Case
If Kiniksa can deliver better-than-expected earnings and show strong revenue growth, it may signal a turnaround in performance and boost investor confidence.
Bear Case
Conversely, if the company misses its earnings or revenue targets again, it could raise concerns about its growth prospects and lead to further declines in the stock price.
EPS
$0.16Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$206MTotal revenue reflects the company's sales performance and growth potential.
Expectations
The print will turn on these two things.
Q1
Will Kiniksa's Q1-2026 EPS meet or exceed the consensus estimate of $0.16?
The market will closely watch this figure as it will indicate the company's ability to recover from previous earnings misses.
Q2
What specific factors contributed to the revenue target of $206 million?
Understanding the drivers behind revenue expectations will help investors gauge the company's growth trajectory and market demand.
Edge
Why consensus could be wrong
The Street may be underestimating Kiniksa's potential for a rebound, as previous earnings surprises indicate volatility that could favor a positive outcome this quarter.
Supporting Evidence
The options market is pricing a smaller move than the historical average, suggesting a potential mispricing of volatility.
Kiniksa's recent performance has shown that it can deliver significant surprises, both positive and negative, indicating a potential for upside.
Insider selling may reflect individual decisions rather than a lack of confidence in the company's future prospects.
Key Risk
If Kiniksa's revenue exceeds $210 million, it could challenge the cautious outlook and shift sentiment positively.
Edge
Pre-commit to what would confirm each case.
This quarter's results are crucial as Kiniksa seeks to demonstrate a turnaround after several disappointing earnings reports.
Bull Confirmed If
An EPS of $0.20 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $0.13 would confirm the bear case, raising concerns about the company's profitability.
Pre-Earnings Positioning
Implied Move
±3.68%
Historical Avg
±10.8%
The options market is pricing in a modest move of about 3.68% around the earnings announcement, suggesting that traders are expecting a relatively stable reaction.
Options are pricing ±3.7% while KNSA has averaged ±10.8% over the last 8 prints — setup is pricing cheap.
30d HV
33.7%
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$388,834.32
8,328 sh
2 insiders
Net
$388,834.32
Net selling
Most Active Insiders· 2 open-market trades
$309,321.25
Net selling
$79,513.07
Net selling
Recent Transactions
Apr 9, 2026 · @ $46.69
6,625 sh
$309,321.25
Apr 9, 2026 · @ $46.69
1,703 sh
$79,513.07
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kiniksa beats expectations, history suggests the stock could rise by an average of 18.59%, confirming a positive turnaround narrative.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance from management.
Miss
A miss could lead to a decline of around 4.58%, reinforcing concerns about the company's growth prospects.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DOMINOS PIZZA INC